The First Affiliated Hospital of Guangxi Medical UniversityGuangxi

of Guangxi, China

The First Affiliated Hospital of Guangxi Medical UniversityGuangxi

of Guangxi, China
SEARCH FILTERS
Time filter
Source Type

Wang T.,Guangxi Medical University | Wang T.,The First Affiliated Hospital of Guangxi Medical UniversityGuangxi | Liu Q.,Guangxi Medical University | Liu Q.,The First Affiliated Hospital of Guangxi Medical UniversityGuangxi | And 12 more authors.
International Journal of Molecular Sciences | Year: 2015

Osteoporosis is a debilitating skeletal disorder with an increased risk of low-energy fracture, which commonly occurs among postmenopausal women. Andrographolide (AP), a natural product isolated from Andrographis paniculata, has been found to have anti-inflammatory, anti-cancer, anti-asthmatic, and neuro-protective properties. However, its therapeutic effect on osteoporosis is unknown. In this study, an ovariectomy (OVX) mouse model was used to evaluate the therapeutic effects of AP on post-menopausal osteoporosis by using micro-computed tomography (micro-CT). Bone marrow-derived osteoclast culture was used to examine the inhibitory effect of AP on osteoclastogenesis. Real time PCR was employed to examine the effect of AP on the expression of osteoclast marker genes. The activities of transcriptional factors NF-κB and NFATc1 were evaluated using a luciferase reporter assay, and the IκBα protein level was analyzed by Western blot. We found that OVX mice treated with AP have greater bone volume (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N) compared to vehicle-treated OVX mice. AP inhibited RANKL-induced osteoclastogenesis, the expression of osteoclast marker genes including cathepsin K (Ctsk), TRACP (Acp5), and NFATc1, as well as the transcriptional activities of NF-κB and NFATc1. In conclusion, our results suggest that AP inhibits estrogen deficiency-induced bone loss in mice via the suppression of RANKL-induced osteoclastogensis and NF-κB and NFATc1 activities and, thus, might have therapeutic potential for osteoporosis. © 2015 by the authors; licensee MDPI, Basel, Switzerland.

Loading The First Affiliated Hospital of Guangxi Medical UniversityGuangxi collaborators
Loading The First Affiliated Hospital of Guangxi Medical UniversityGuangxi collaborators